<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02869321</url>
  </required_header>
  <id_info>
    <org_study_id>2014-003352-32</org_study_id>
    <nct_id>NCT02869321</nct_id>
  </id_info>
  <brief_title>Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy</brief_title>
  <acronym>ANTALGIP</acronym>
  <official_title>Evaluation of Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with Head &amp; Neck Squamous Cell Carcinoma often need a gastrostomy. It can be
      performed with a radiological approach. This procedure is usually not performed under general
      anesthesia, but local anesthesia is not sufficient to counteract pain due to gastric
      insufflation and incision of the abdominal wall. Standard analgesic treatments are usually
      not well-fitted due to onset of action or route of administration. An alternative solution
      could be fentanyl nasal spray, a treatment with a fast onset of action and with easy use
      allowing repetition if needed, during the procedure.

      The purpose of this study is to compare analgesic efficacy of nasal instillation of PECFENT®
      to usually administered morphinic analgesic treatment with fast onset of action (ORAMORPH®),
      in radiologic percutaneous gastrostomy tube placement:

        -  during the procedure

        -  following the procedure (measured by Visual Analog Scale (VAS) for Pain at 15 min, 30
           min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours and 12 hours after procedure).

      Secondary purposes are to compare easiness of 2 treatments and their adverse effects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Intensity of breakthrough pain during the gastrostomy</measure>
    <time_frame>during gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>15 min after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>30 min after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>1 hour after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>2 hours after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>3 hours after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>4 hours after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>6 hours after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Intensity of pain following the gastrostomy</measure>
    <time_frame>12 hours after gastrostomy</time_frame>
    <description>Pain measured by VAS</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Necessity of a second analgesic treatment after gastrostomy</measure>
    <time_frame>up to 12 hours from gastrostomy</time_frame>
    <description>in case of Pain VAS &gt;4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of satisfaction of patient with analgesic efficacy</measure>
    <time_frame>up to 1 day from gastrostomy</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of satisfaction of staff with analgesic efficacy and easiness to use of treatments</measure>
    <time_frame>up to 1 day from gastrostomy</time_frame>
    <description>Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance of times of administration of treatments with the procedure</measure>
    <time_frame>day 0</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of adverse effects of administered drugs</measure>
    <time_frame>up to 24 hours post gastrostomy</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Gastrostomy</condition>
  <condition>Breakthrough Pain</condition>
  <condition>Upper Aerodigestive Tract Neoplasms</condition>
  <arm_group>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of Morphine Sulfate Placebo and Fentanyl
Morphine Sulfate Placebo: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy
Fentanyl: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy
Administration 1+2 if pain after 4 hours from gastrostomy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Morphine Sulfate</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration of Morphine Sulfate and Fentanyl Placebo
Morphine Sulfate: oral solution administered through nasogastric tube, 10% of daily dose of morphine of background treatment, 1 hour before gastrostomy
Fentanyl Placebo: nasal spray solution, 100 µg pulverisation, 15 min before gastrostomy, if not efficacy second dose after 15 min during gastrostomy
Administration 1+2 if pain after 4 hours from gastrostomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <arm_group_label>Fentanyl</arm_group_label>
    <other_name>PECFENT®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate</intervention_name>
    <arm_group_label>Morphine Sulfate</arm_group_label>
    <other_name>ORAMORPH®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl placebo</intervention_name>
    <arm_group_label>Morphine Sulfate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine Sulfate placebo</intervention_name>
    <arm_group_label>Fentanyl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Gastrostomy</intervention_name>
    <arm_group_label>Fentanyl</arm_group_label>
    <arm_group_label>Morphine Sulfate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient care for cancer of the upper aerodigestive tract (except sinonasal)

          -  &gt; 18, all weights, all sexes

          -  Under balanced background opioid treatment since longer than 7 days (VAS &lt; 5)

          -  Needing a radiologic gastrostomy under local anesthesia

          -  Informed consent

          -  Affiliation to social security plan

          -  Preliminary medical examination

        Exclusion Criteria:

          -  Non balanced morphinic treatment : modification of analgesic treatment during 7
             previous days

          -  Radiotherapy of nasal fossae/sinus

          -  Technical impossibility or contraindication to PECFENT®, ORAMORPH® and associated
             drugs

          -  Impossibility of pain evaluation by patient

          -  Belonging to protected class: pregnant or breastfeeding woman, person deprived of
             liberty for judiciary or administrative decision, under-18, person under legal
             protection or incapable of giving consent, person in life-and-death emergency
             incapable of giving a preliminary consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrice GALLET</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service ORL - CHU NANCY - France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Patrice GALLET</last_name>
    <email>p.gallet@chru-nancy.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service ORL - CHU NANCY</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrice GALLET</last_name>
    </contact>
    <investigator>
      <last_name>Bruno TOUSSAINT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2016</study_first_submitted>
  <study_first_submitted_qc>August 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2016</study_first_posted>
  <last_update_submitted>August 19, 2016</last_update_submitted>
  <last_update_submitted_qc>August 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breakthrough Pain</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Analgesics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

